MX2019013160A - Metodos de tratamiento selectivo del asma usando antagonistas de il-17. - Google Patents

Metodos de tratamiento selectivo del asma usando antagonistas de il-17.

Info

Publication number
MX2019013160A
MX2019013160A MX2019013160A MX2019013160A MX2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A
Authority
MX
Mexico
Prior art keywords
antagonists
methods
treating asthma
selectively treating
asthma
Prior art date
Application number
MX2019013160A
Other languages
English (en)
Inventor
Schmidt Grant Sarah
Kazani Shamsah
Khokhlovich Edward
Laramie Jason
Martin Strieter Robert
Ann Thornton-Wells Tricia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019013160A publication Critical patent/MX2019013160A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La divulgación se refiere a métodos, regímenes de tratamiento, usos, equipos y terapias para el tratamiento del asma, tal como el asma grave, empleando antagonistas de IL-17 en una población de pacientes definida por la concentración sérica de IgE y, opcionalmente, también un recuento de eosinófilos en sangre periférica.
MX2019013160A 2017-05-05 2018-05-04 Metodos de tratamiento selectivo del asma usando antagonistas de il-17. MX2019013160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05
PCT/IB2018/053106 WO2018203289A1 (en) 2017-05-05 2018-05-04 Methods of selectively treating asthma using il-17 antagonists

Publications (1)

Publication Number Publication Date
MX2019013160A true MX2019013160A (es) 2020-02-05

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013160A MX2019013160A (es) 2017-05-05 2018-05-04 Metodos de tratamiento selectivo del asma usando antagonistas de il-17.

Country Status (13)

Country Link
US (1) US10676522B2 (es)
EP (1) EP3619536A1 (es)
JP (1) JP2020518604A (es)
KR (1) KR20190142398A (es)
CN (1) CN110582702A (es)
AU (1) AU2018263159A1 (es)
BR (1) BR112019023141A2 (es)
CA (1) CA3062179A1 (es)
CL (1) CL2019003161A1 (es)
MX (1) MX2019013160A (es)
RU (1) RU2019139387A (es)
TW (1) TW201842933A (es)
WO (1) WO2018203289A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN115362173A (zh) * 2020-04-17 2022-11-18 伊莱利利公司 呼吸系统疾病的治疗

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP2481753B1 (en) 2005-12-13 2018-04-18 Eli Lilly and Company Anti-IL-17 Antibodies
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2271770B1 (en) 2008-03-31 2018-08-22 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
AU2009296299A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human IL 17 and uses thereof
SG11201505330QA (en) 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
CA2924873A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
US20160000936A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3191120B1 (en) * 2014-09-10 2024-04-10 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Also Published As

Publication number Publication date
US10676522B2 (en) 2020-06-09
KR20190142398A (ko) 2019-12-26
RU2019139387A (ru) 2021-06-07
BR112019023141A2 (pt) 2020-07-28
CN110582702A (zh) 2019-12-17
CA3062179A1 (en) 2018-11-08
US20180319881A1 (en) 2018-11-08
JP2020518604A (ja) 2020-06-25
TW201842933A (zh) 2018-12-16
CL2019003161A1 (es) 2020-02-07
AU2018263159A1 (en) 2019-11-07
WO2018203289A1 (en) 2018-11-08
EP3619536A1 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
PH12015500196A1 (en) Methods of treating a tauopathy
MY163057A (en) Means and methods for trating dlblcl
MY196858A (en) Method
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
SG10201902594QA (en) Peptidomimetic macrocycles and uses thereof
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
PH12018501443A1 (en) Methods of administering hepcidin
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
TW201612189A (en) Sterile chromatography and manufacturing processes
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
PH12016500753A1 (en) Antibodies specific to fcrn
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
MX2021008305A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.